SB-509
SB-509-0801
Phase 2 small_molecule completed
Quick answer
SB-509 for Amyotrophic Lateral Sclerosis is a Phase 2 program (small_molecule) at SANGAMO THERAPEUTICS, INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- SANGAMO THERAPEUTICS, INC
- Indication
- Amyotrophic Lateral Sclerosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed